CardioVere strives to improve the patient journey. Precise intervention improves patient care, and impacts caregivers, mortality, readmissions, length of stay, and cost.
CardioVere’s mission is to provide precise measurement of peripheral edema and change the standard of care for Heart Failure.
Lower Cost of Care
CardioVere’s parent company, ChemImage is a pioneer in Molecular Chemical Imaging (MCI). We have extensive experience in advanced surgical imaging and are the first company formed to bring MCI to materials analysis. As the only company with this level of expertise, we have been able to develop complex biological detection for healthcare optimization.
ChemImage-developed patents protect this peripheral edema monitoring device that will be highly differentiated and first to market. Patents are available for exclusive license under defined field of use. To learn more about ChemImage, visit us at chemimage.com.